Galectin Therapeutics Inc. (GALT)

[JERZYATP1]

Regarding post#2186, in any case the result for Patient 4 (66% reduction of PAS1 score) is really encouraging, and longer dosing of the patients is properly called for. In that connection it's rather nice that GR-MD-02 has a fine safety profile. For comparison with Humira see the Humira website. The safety profile of Humira is nasty. In a previous post I alluded to Pharma throwing monkey wrenches at diseases. Humira is an antibody which blocks TNF-alpha
which is a cell signaling protein intimately involved in the immune system. While TNF blocking can curtail psoriasis downstream it can incur other effects in the immune system that are very unsafe.
The causation of psoriasis appears to be at least partially genetic,
plus a variety of environmental triggers.
That Humira is an antibody means additionally it's relatively expensive. And to throw an antibody into the system is a risky proposition for patients. I'd sure opt for GR-MD-02.